Ethical Issues and Risk/Benefit Assessment of Iron Chelation Therapy: Advances with Deferiprone/Deferoxamine Combinations and Concerns about the Safety, Efficacy and Costs of Deferasirox-Reference-Cited by-同舟云学术

Ethical Issues and Risk/Benefit Assessment of Iron Chelation Therapy: Advances with Deferiprone/Deferoxamine Combinations and Concerns about the Safety, Efficacy and Costs of Deferasirox

Published:2008-01 Issue:1-2 Volume:32 Page:1-15
ISSN:0363-0269
Container-title:Hemoglobin
language:en
Short-container-title:Hemoglobin

Author:

Kontoghiorghes George J.

Publisher

Informa UK Limited

Subject

Biochemistry, medical,Clinical Biochemistry,Genetics(clinical),Hematology

Link

http://www.tandfonline.com/doi/pdf/10.1080/03630260701726533

Reference32 articles.

1. Advances in Iron Overload Therapies. Prospects for Effective Use of Deferiprone (L1), Deferoxamine, the New Experimental Chelators ICL670, GT56-252, L1NAll and their Combinations

2. Benefits and Risks of Deferiprone in Iron Overload in Thalassaemia and Other Conditions

3. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register

4. The Design and Development of Deferiprone (L1) and Other Iron Chelators for Clinical Use: Targeting Methods and Application Prospects

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Towards Clinical Development of Scandium Radioisotope Complexes for Use in Nuclear Medicine: Encouraging Prospects with the Chelator 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA) and Its Analogues;International Journal of Molecular Sciences;2024-05-29

2. Puzzling out iron complications in cancer drug resistance;Critical Reviews in Oncology/Hematology;2022-10

3. Questioning Established Theories and Treatment Methods Related to Iron and Other Metal Metabolic Changes, Affecting All Major Diseases and Billions of Patients;International Journal of Molecular Sciences;2022-01-25

4. Anti‑CD206 antibody‑conjugated Fe3O4‑based PLGA nanoparticles selectively promote tumor‑associated macrophages to polarize to the pro‑inflammatory subtype;Oncology Letters;2020-09-28

5. DIBI, a novel 3-hydroxypyridin-4-one chelator iron-binding polymer, inhibits breast cancer cell growth and functions as a chemosensitizer by promoting S-phase DNA damage;BioMetals;2019-10-17